Objective To systematically summarize and evaluate the findings of existing studies about
patients' perceptions of biosimilars by assessing their attitudes and knowledge. Methods We …

Background and aims The aim of this survey was to find out whether the perspectives of
patients with inflammatory bowel disease concerning biosimilars have changed since the …

BACKGROUND: Few surveys about biosimilars have been conducted among US patients.
OBJECTIVE: To evaluate attitudes about biosimilars among patients with rheumatoid …

Background The adoption of oncology biosimilars has been slow in the USA, which may be
attributed in part to stakeholder perceptions and lack of operational guidance that supports …

Oncology biologics are one of the fastest-growing segments of pharmaceutical
development, bringing more options to patients, including those with human epidermal …

Einleitung Mit Einführung der ersten Trastuzumab-Biosimilars im Sommer 2018 haben
biosimilare Antikörper beim Mammakarzinom Einzug in die gynäkologische Onkologie …

Background: There are gaps in gastroenterologist team members' understanding of various
topics related to biosimilars. We aimed to examine perspectives, views, and attitudes toward …

BACKGROUND There is a lack of studies and educational programs focused on biosimilars
and shared decision-making among patients diagnosed with various rheumatic diseases …

Objectives: To conduct a systematic review of the literature to assess multiple stakeholder
perspectives on the facilitators and barriers to adoption of biosimilars with a global …